FDA Rebidding Part 11 Contract, New Regulation Not Imminent

Drug GMP Report
Although the FDA is rebidding its contract for a consultant to help rewrite the Part 11 regulation and related guidance documents, publication of a revision is not expected in the near future.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $20.00